Dr Adam Gillman
Post-Doctoral Research Associate
Dr Adam Gillman gained his PhD in Molecular and Cellular Virology at Imperial College London, studying the role of the viral oncogene EBNA3C in Epstein-Barr virus driven B cell transformation in the Allday/White/Farrell groups.
After finishing his thesis, he joined OXGENE (previously Oxford Genetics) a CRDMO spin out from Oxford university founded by Dr Ryan Cawood and Prof. Len Seymour working in the gene therapy space. As a research scientist he developed their AAV platform and novel bioprocessing platform, securing a patent, before moving to Barinthus Biotherapeutics (previously Vaccitech) joining the vector platforms research team headed by Sarah Sebastian. Adam joined the Gilbert group as a post-doc in August 2024, working on developing Adenovirus vector platforms.